Hints and tips:
Related Special Reports
...guidance from the Centers for Medicare and Medicaid Services (CMS)....
...Instead, only about 5,600 patients had been approved for treatment by early April, according to a registry by the Centers for Medicare & Medicaid Services shared with the Financial Times....
...The Centers for Medicare & Medicaid Services said last month that Medicare Part D drug benefit plans will cover weight loss medicines when they are approved to treat a separate medical problem, such as heart...
...The pharmaceutical company said on Tuesday it had filed suit against the US Department of Health and Human Services and Centers for Medicare and Medicaid Services....
...The pharmaceutical company said on Tuesday it filed a lawsuit against the US Department of Health and Human Services as well as the Centers for Medicare and Medicaid over what it calls an “innovation-damaging...
...The drugs on the list cost Medicare more than $50bn in the 12 months to May 31, said the Centers for Medicare and Medicaid Services....
...In a filmed exchange, Barkan asked Flake to vote against his party’s tax-cut bill, which Barkan said would trigger cuts to spending on social services — including Medicare disability payments for the sick...
...The process is due to begin in earnest next week when the Centers for Medicare & Medicaid Services (CMS) is due to publish a list of 10 expensive drugs that will be the focus of the negotiation....
...Cancer, stroke and diabetes medications made by Merck, Johnson & Johnson and Bristol Myers Squibb are among the first tranche of medications selected for negotiation....
...The decision by the Centers for Medicare & Medicaid Services to provide coverage for the treatment is crucial to enable a wide rollout....
...The company said a decision by Centers for Medicare and Medicaid Services to restrict financial support for Leqembi to Alzheimer’s patients whose doctors participate in a health agency database could have...
...The process is due to begin in earnest in September when the Centers for Medicare & Medicaid Services (CMS) is due to identify 10 expensive drugs that will be the focus of the negotiation....
...The Centers for Medicare & Medicaid Services did not respond to a request for comment....
...for Medicare and Medicaid Services, a US government agency, last week....
...In the wake of the controversy over the FDA approval of Biogen’s aducanumab, the US Centers for Medicare and Medicaid Services said only patients taking part in a clinical trial would benefit from reimbursement...
...Cheung said Eisai would apply for full approval for Leqembi imminently and talk to the US Centers for Medicare & Medicaid Services about relaxing reimbursement restrictions for the treatment....
...One of its biggest setbacks was the disastrous launch of aducanumab, which prompted the US Centers for Medicare & Medicaid Services to severely restrict reimbursement for all amyloid-reducing monoclonal...
...States and local government areas are also starting to receive some of the $26bn in funds extracted in settlements with Johnson & Johnson, Cardinal Health, McKesson and AmerisourceBergen for their role in...
...“Based on these data, we are highly confident in lecanemab’s approval and eventual Centers for Medicare and Medicaid Services (CMS) reimbursement,” he said....
...(Mercatus Center podcast) — Commutes are what is keeping offices empty. (WSJ) — Dominic Cummings unloads on Boris and Carrie Johnson....
...In a draft decision published on Tuesday, the Centers for Medicare & Medicaid Services said its thorough review process that found that while there may be potential for promise with the treatment, there...
...The Centers for Medicare & Medicaid Services issued a formal decision on Thursday limiting reimbursement for Biogen’s drug to just a few thousand patients enrolled in clinical trials rather than the estimated...
...The unusual price cut comes as the US Centers for Medicare and Medicaid Services is considering whether to cover the drug in Medicare, the programme for senior citizens....
...Strict curbs put on Biogen’s Alzheimer’s treatment The Centers for Medicare & Medicaid Services has upheld an earlier draft ruling restricting access to Biogen’s Alzheimer’s treatment Aduhelm....
International Edition